Xiaoqi Sun, PhD
About Me
Dr. Xiaoqi (Kevin) Sun is an Assistant Professor in the Department of Immunology and Immunotherapy, the Icahn Genomics Institute (IGI), the Lipschultz Precision Immunology Institute (PrIISM), and Tisch Cancer Institute. Dr. Sun earned his Ph.D. from the University of Michigan in 2021 and worked as a Scientist and the Non-Viral Delivery Team Head at Editas Medicine from 2021 to 2024. Dr. Sun’s pioneering work has introduced the concept of "metalloimmunotherapy," demonstrating its potential as a new class of immunotherapy and leading to the creation of Saros Therapeutic (Nature Nanotechnology 2021, Nature Biomedical Engineering 2024). He has also introduced the concept"RBC-aAPC" for T cell training, a novel cell therapy system adopted by Rubius Therapeutics for drug development and tested in Phase I clinical trial. Additionally, he co-developed a series of cancer neoantigen vaccines based on lipid nanodiscs for personalized cancer immunotherapy, laying the foundation of EVOQ Therapeutics. His contributions also extend to the development of multiple RNA LNP-based gene editing drug candidates in industry and a highly effective ex-vivo gene knock-in tool "SLEEK" (Nature Biotechnology 2023).
Dr. Sun’s research group in Mount Sinai is interested in three key research areas: 1) Utilizing nanoparticle and molecular engineering to create novel approaches for immune cell reprogramming; 2) Advancing next-generation gene editing through innovations in non-viral delivery systems; 3) Employing fundamental principles of immunology and pharmaceutical sciences to develop new therapeutic strategies for cancer, infectious, and autoimmune/inflammatory diseases.
Lab website: https://www.igen-lab.com/
Language
Position
Research Topics
Anti-Tumor Therapy, Gene editing, Immunological Tolerance, Inflammation, Inflammatory Bowel Disease (IBD)
Multi-Disciplinary Training Areas
Genetics and Genomic Sciences [GGS], Immunology [IMM]
About Me
Dr. Xiaoqi (Kevin) Sun is an Assistant Professor in the Department of Immunology and Immunotherapy, the Icahn Genomics Institute (IGI), the Lipschultz Precision Immunology Institute (PrIISM), and Tisch Cancer Institute. Dr. Sun earned his Ph.D. from the University of Michigan in 2021 and worked as a Scientist and the Non-Viral Delivery Team Head at Editas Medicine from 2021 to 2024. Dr. Sun’s pioneering work has introduced the concept of "metalloimmunotherapy," demonstrating its potential as a new class of immunotherapy and leading to the creation of Saros Therapeutic (Nature Nanotechnology 2021, Nature Biomedical Engineering 2024). He has also introduced the concept"RBC-aAPC" for T cell training, a novel cell therapy system adopted by Rubius Therapeutics for drug development and tested in Phase I clinical trial. Additionally, he co-developed a series of cancer neoantigen vaccines based on lipid nanodiscs for personalized cancer immunotherapy, laying the foundation of EVOQ Therapeutics. His contributions also extend to the development of multiple RNA LNP-based gene editing drug candidates in industry and a highly effective ex-vivo gene knock-in tool "SLEEK" (Nature Biotechnology 2023).
Dr. Sun’s research group in Mount Sinai is interested in three key research areas: 1) Utilizing nanoparticle and molecular engineering to create novel approaches for immune cell reprogramming; 2) Advancing next-generation gene editing through innovations in non-viral delivery systems; 3) Employing fundamental principles of immunology and pharmaceutical sciences to develop new therapeutic strategies for cancer, infectious, and autoimmune/inflammatory diseases.
Lab website: https://www.igen-lab.com/
Language
Position
Research Topics
Anti-Tumor Therapy, Gene editing, Immunological Tolerance, Inflammation, Inflammatory Bowel Disease (IBD)
Multi-Disciplinary Training Areas
Genetics and Genomic Sciences [GGS], Immunology [IMM]
